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Osteoarthritis and Management
Basem Al-Omari*School of Health and Life Science, University of Northumbria, UK
AbstractOsteoarthritis (OA) is a degenerative disease that causes pain, limitation of movement, and disability. The diagnosis of OA requires clinical examination, pathology, and/or radiography. OA has no cure, the current available treatment focuses on pain management and improving the quality of life. This treatment includes non-pharmacological treatment such as exercises and physiotherapy, pharmacological such as 
acetaminophen, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and opioids, and surgical interventions such as joint replacement.  
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Osteoarthritis BackgroundOA is a chronic disabling and intermittently or slowly progressive joint degenerative disease [1]. It is the most common form of arthritis; it involves degradation of the articular cartilage, synovium, and subchondral bones [2] causing joint pain, functional limitation and reduced quality of life [3]. OA can affect any joint. However, the knee, hip, hand and spine are the most common sites of OA, but it can also occur in the ankles and wrists [4].OA can be diagnosed clinically, pathologically, or radiographically which is the most 
frequent definition for OA [5]. Initially, clinicians may define OA by examining the patients, signs and symptoms, and risk factors. The most common radiographic grading system for OA is Kellgren and Lawrence grade, which score the severity of OA on a scale of 0 to 4 [6]. A score 
of 2 or above in Kellgren and Lawrence indicates definite radiographic OA [7].The prevalence of OA increases with age and it affects as many as 80% of the population 
over 75 years of age [8]. Generally, women are at greater risk of OA and have more severe symptoms than men, especially after menopausal age [9]. The World Health Organisation (WHO) estimates that OA affects 9.6% of men and 18% of women over 60 years of age [10]. In the United Kingdom (UK), OA is considered to be one of the leading causes of pain and disability [11]. It is also responsible for a large proportion of physician time, hospitalisations, and time lost from work in the Western countries [12]. As life expectancy and the numbers of older people in the population are increasing, it is expected that OA will be the fourth leading cause of disability by the year 2020 [13]. 
Osteoarthritis ManagementAt the present time, there is still no cure for OA [14]. The treatments that are currently available for OA are aiming for pain reduction, correcting deformities, and improving joint 
function to enhance the quality of the patient’s life [15,16].
Guidelines for the management of OA pain are available from a number of sources e.g. 
NICE OA guidelines [15] and Zhang et al. [17] recommendations [15,16]. Generally, OA treatment includes non-pharmacological, pharmacological, and surgical interventions [18]. Although non-pharmacological treatments of OA such as exercise and physiotherapy revealed a modest effect in reducing symptoms, one of their main advantages is that they pose no inherent risks [18]. Therefore, the non-pharmacological treatments are recommended at all 
levels of OA severity [15,18]. 
In the UK, the National Institute of Health and Clinical Excellence (NICE) [15] recommend exercise as the core treatment for people with OA, irrespective of age, comorbidity, pain 
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severity or disability. This core treatment is a treatment that should be considered for every person with OA. However, as a treatment for OA, exercise is not necessarily or always successful alone [20]. In this case, pharmaceutical treatments for OA are considered. 
Pharmaceutical treatments for OA consist of different types 
of medication including pain relieving and anti-inflammatory medications [20]. Most guidelines recommend acetaminophen (paracetamol) as the initial oral drug [21]. The NICE OA guideline suggests that paracetamol should be offered for pain relief in 
addition to exercise [15]. In patients who do not experience adequate symptomatic relief with exercise and paracetamol, alternative or additional pharmacological medication such as nonsteroidal anti-
inflammatory drugs (NSAIDs) should be considered [15,22,23]. 
NSAIDs are made in different forms and have different methods of 
administration e.g. oral, topical and rectal. Oral NSAIDs have shown risk of adverse effects in relation to systems such as gastrointestinal, 
liver and cardio-vasculara, which is higher than paracetamol or 
topical NSAIDs [2,20,23]. Thus, the main UK arbiter of approved effective clinical treatments for use in the National Health Service 
recommends that topical NSAIDs should be considered ahead 
of oral NSAIDs, Cyclo-oxygenase 2 (COX-2) inhibitors or opioids 
[15,24]. Although NSAIDs and COX-2 inhibitors may be regarded as 
a single drug class of ‘NSAIDs’, NICE OA guidelines continues to use the two terms for clarity, and because of the differences in the side 
effect profiles. When the combination of paracetamol with NSAIDs 
fails, then the addition of opioid analgesics is considered [8,15].Surgical treatment should be the last resource of treatment for 
OA [15]. Nonetheless, when non-surgical treatments fail and there is prolonged and established functional limitation and severe pain that have a substantial impact on the quality of life, referral for joint replacement surgery is recommended [2].
Figure 1: Summary of the treatments adopted from NICE OA guideline [15].Figure 1 shows the order of treatment to be considered for 
people with OA as recommended by NICE OA guidelines [15]. The treatments are arranged in the order in which they should be considered for people with OA starting from the central circle. The central circle includes non-pharmaceutical treatment that should 
be considered for every OA patient at all stages of severity. Going outward from the central circle, the middle circle shows the next treatment that should be considered for OA patients combined with 
the central circle treatment. Finally, the external circle in the figure includes treatments that should be considered if the treatment in the central and middle circle failed. It is vital that individual needs, risk factors and preferences are considered at every stage of treatment.
ConclusionOA is a chronic disabling disease that causes pain and limitation of movement. It is considered to be one of the leading causes of disability and time lost from work. There is still no cure for OA. 
Therefore, symptomatic treatment is essential to reduce pain and 
improve the quality of life. The first and core treatment for OA should start with non-pharmacological non-surgical management such as exercises and physiotherapy. If exercise and physiotherapy are not successful or patients are still experiencing pain or movement limitation, further pharmacological treatment could be used in conjunction with the core treatment. Surgical treatment should always be the last resource for OA treatment.
Future directions
Pharmacological treatment for OA, such as NSAIDs and opioids have several risks of adverse effects that may have an impact on patients’ health. Therefore, it is vital that patients are informed of all adverse effects associated with these medications. This will aid the shared decision-making process between patients and their clinicians and will facilitate an informed decision made by the patients to opt for the pharmacological treatment or not.
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